摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(2-氯-6-甲基苯基)苯甲酰胺 | 10286-86-9

中文名称
N-(2-氯-6-甲基苯基)苯甲酰胺
中文别名
——
英文名称
N-(2-chloro-6-methylphenyl)benzamide
英文别名
N-benzoyl-2-chloro-6-methylaniline
N-(2-氯-6-甲基苯基)苯甲酰胺化学式
CAS
10286-86-9
化学式
C14H12ClNO
mdl
——
分子量
245.708
InChiKey
KCMJCTKSNLUIOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    29.1
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:60097ad44cd6fa45fc6cfe252e82832d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists
    摘要:
    The development of very high affinity, selective, and bioavailable h5-HT2A receptor antagonists is described. By investigation of the optimal position for the basic nitrogen in a series of 2-phenyl-3-piperidylindoles, it was found that with the basic nitrogen at the S-position of the piperidine it was not necessary to further substitute the piperidine in order to obtain good binding at h5-HT2A receptors. This meant the compounds no longer had high affinity at the IKr potassium channel, an issue with previous series of 2-aryl-3-(4-piperidyl)indoles. Improvements could be made to oral bioavailability in this series by reduction of the pK(a) of the basic nitrogen, by adding a fluorine atom to the piperidine ring, leading to 3-(4-fluoropiperidin-3-yl)-2-phenyl-1H-indole (17). Metabolic studies with this compound identified oxidation at the B-position of the indole as a major route in vitro and in vivo in rats. Blocking this position with a fluorine atom led to 6-fluoro-3-(4-fluoropiperidin-3-yl)-2-phenyl-1H-indole (22), an antagonist with 0.06 nM affinity for h5-HT2A receptors, with bioavailability of 80% and half-life of 12 h in rats.
    DOI:
    10.1021/jm0004998
  • 作为产物:
    描述:
    甲基硝基苯氯化亚砜碳酸氢钠氯化铵 作用下, 以 乙醚 为溶剂, 反应 2.0h, 生成 N-(2-氯-6-甲基苯基)苯甲酰胺
    参考文献:
    名称:
    Ayyangar, N. R.; Kalkote, U. R.; Nikrad, P. V., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 9, p. 872 - 877
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Exploiting the Reactivity of Isocyanide: Coupling Reaction between Isocyanide and Toluene Derivatives Using the Isocyano Group as an N1 Synthon
    作者:Zhiqiang Liu、Xinglu Zhang、Jianxiong Li、Feng Li、Chunju Li、Xueshun Jia、Jian Li
    DOI:10.1021/acs.orglett.6b01928
    日期:2016.8.19
    An unusual oxidative coupling reaction of isocyanide and toluene derivatives using tetrabutylammonium iodide (TBAI) as a catalyst is disclosed. The experimental results and mechanistic study show that the isocyano group acts formally as an N1 synthon during the transformation, thus expanding the reactivity profile of isocyanide.
    公开了使用碘化四丁铵(TBAI)作为催化剂的异氰酸酯和甲苯衍生物的不寻常的氧化偶联反应。实验结果和机理研究表明,异氰酸酯基团在转化过程中正式作为N1合成子起作用,从而扩大了异氰酸酯的反应活性。
  • [EN] PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF<br/>[FR] PYRROLO [2, 3-B] PYRIDINES OU PYRROLO [2, 3-B] PYRAZINES COMME INHIBITEUR DE HPK1 ET LEUR UTILISATION
    申请人:BEIGENE LTD
    公开号:WO2019238067A1
    公开(公告)日:2019-12-19
    Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.
    本文披露了一种公式(AIII)或(III)的化合物,或其立体异构体,或其药用可接受的盐,以及包含该化合物的药物组合物。还披露了一种利用本文披露的化合物治疗HPK1相关疾病或疾病的方法。
  • Atroposelective Catalytic Asymmetric Allylic Alkylation Reaction for Axially Chiral Anilides with Achiral Morita–Baylis–Hillman Carbonates
    作者:Shou-Lei Li、Chen Yang、Quan Wu、Han-Liang Zheng、Xin Li、Jin-Pei Cheng
    DOI:10.1021/jacs.8b06014
    日期:2018.10.10
    A highly efficient method to access axially chiral anilides through asymmetric allylic alkylation reaction with achiral Morita-Baylis-Hillman carbonates by using a biscinchona alkaloid catalyst was reported. Through the atroposelective approach, a broad range of axially chiral anilide products with different acyl groups, such as substituted phenyl, naphthyl, alkyl, enyl, styryl, and benzyl, were generated
    报道了一种通过使用双金鸡纳生物碱催化剂与非手性 Morita-Baylis-Hillman 碳酸酯的不对称烯丙基烷基化反应获得轴向手性苯胺的高效方法。通过阻变选择性方法,以非常好的收率、中等至极好的顺式:反式比率生成了范围广泛的具有不同酰基的轴向手性苯胺产物,例如取代的苯基、萘基、烷基、烯基、苯乙烯基和苄基,以及良好的对映选择性。该反应可以放大,并且轴向手性苯胺的合成效用通过转化得到了证明。此外,引入线性自由能关系分析来研究反应。
  • Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors
    作者:Shivaputra Patil、Shantaram Kamath、Tino Sanchez、Nouri Neamati、Raymond F. Schinazi、John K. Buolamwini
    DOI:10.1016/j.bmc.2006.11.026
    日期:2007.2.1
    A new series of phenanthridinone derivatives, and diketo acid analogs, as well as related phenanthrene and anthracene diketo acids have been synthesized and evaluated as HIV integrase (IN) inhibitors. Several new beta-diketo acid analogs with the phenanthridinone scaffold replaced by phenanthrene, anthracene or pyrene exhibited the highest IN inhibitory potency. There is a general selectivity against
    已经合成了一系列新的菲啶酮衍生物和二酮酸类似物,以及相关的菲和蒽二酮酸,并将其作为 HIV 整合酶 (IN) 抑制剂进行了评估。菲啶酮支架被菲、蒽或芘取代的几种新的 β-二酮酸类似物表现出最高的 IN 抑制效力。对整合酶链转移步骤有普遍的选择性。最有效的 IN 是 2,4-dioxo-4-phenanthren-9-yl-butyric acid (27f) 与 IC(50) 的 0.38microM 对整合酶链转移。菲二酮酸 27d-f 比相应的菲啶酮二酮酸 16 (IC(50)=65microM) 更有效 (IC(50)=2.7-0.38microM),表明菲啶酮系统中的极性酰胺桥相对于更亲脂的菲系统降低了抑制活性。这可能与化合物的芳基可能结合到整合酶活性位点的亲脂口袋上,如对接模拟所建议的。分子模型还表明活性位点 Mg(2+) 螯合的有效性有助于 IN 抑制效力。最后,一些有效的化合物抑制
  • Palladium-Catalyzed Synthesis of Benzimidazoles and Quinazolinones from Common Precursors
    作者:Jessie E. R. Sadig、Radleigh Foster、Florian Wakenhut、Michael C. Willis
    DOI:10.1021/jo301805d
    日期:2012.11.2
    utilized as complementary precursors for the synthesis of important heterocycles. The synthesis of N-substituted benzimidazoles was possible from the palladium-catalyzed reaction of both classes of substrate with a variety of N-nucleophiles. The use of the imidate precursor for the synthesis of N-substituted quinazolinones by incorporation of a palladium-catalyzed aminocarbonylation reaction has also been
    N-(邻卤代苯基)亚氨基酰氯和相应的酰亚胺化物易于制备,并且可用作合成重要杂环的互补前体。N-取代的苯并咪唑的合成可能是由两类底物与多种N-亲核试剂的钯催化反应所致。还已经证明了亚氨酸酯前体通过掺入钯催化的氨基羰基化反应用于合成N-取代的喹唑啉酮的用途。两种方法都可以耐受各种官能团。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐